Athira Pharma - מכפיל EV/Sales ATHA

Athira Pharma, Inc. (ATHA) expenses depend on the outcome of FDA tests, which determines capital inflows. The EV-to-sales ratio visualizes the balance between market price and actual revenues, while 0.00 reflects the most recent value of the metric. Value growth is supported by the brand's authority in neuron regeneration and the application of AI robotics to create compounds against Alzheimer's disease.
פילוחי מדדים פיננסיים ומדדי שוק עבור Athira (ATHA)

This ratio compares the total enterprise value to sales volume, excluding the impact of debt load to identify the actual market overvaluation of assets relative to operating income. Amidst the portfolio revision of Athira Pharma, Inc. (ATHA) and rising restructuring costs, the enterprise value-to-revenue chart signals a critical disconnect between the speculative price and the actual efficiency of the business.